CSL names Deborah Waterhouse as chief executive from February 2027
Australian biotech company CSL has appointed Deborah Waterhouse as CEO and managing director from February 1, 2027, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Australia's CSL said Deborah Waterhouse has been appointed chief executive officer and managing director effective February 1, 2027, Reuters reported.
Interim CEO Gordon Naylor will remain in his role until February next year. Waterhouse's base salary is set at 1.50 million pounds sterling a year.
why it matters
A leadership change at a large biotech group usually draws investor attention to strategy and growth plans. The handover does not change financial results on its own, but it signals the direction the company may take in the coming years.
market impact
CSL (ASX): the leadership change may shift investor expectations about the company's strategy
tags
instruments
sources
- CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director — Reuters, 21 October 2026 at 05:42 UTC
- Australia's CSL appoints Deborah Waterhouse as CEO — Reuters, 21 October 2026 at 05:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗